3207
document
Comparison of different long-term asthma treatments in subjects with mild-to-moderate asthma . In order to compare the efficacy of different asthma treatment in subjects with mild-to-moderate asthma , three groups of 11 patients were treated with nedocromil sodium ( NS ) , beclomethasone dipropionate ( BDP ) and beclomethasone dipropionate plus salmeterol ( BDP + S ) in an open , randomized study . Symptom score , peak expiratory flow ( PEF ) maximal amplitude , forced expiratory volume in one second ( FEV1 ) , and methacholine reactivity were measured at the baseline and at intervals of 3 months up to 12 months . After 3 months , symptoms reduced significantly in all treatment groups , while PEF variability improved in BDP and BDP + S groups ; FEV1 and bronchial responsiveness to methacholine were significantly improved in comparison with baseline value in the BDP + S group only . No significant difference was observed after 6 and 12 months of treatment in PEF variability , FEV1 or bronchial hyperreactivity in the NS group compared with baseline values , while a significant difference was observed in symptom score . BDP group showed a significant improvement in FEV1 and bronchial reactivity to methacholine after 6 and 12 months of treatment . In the BDP + S group , the improvement in symptoms and pulmonary function persisted until the end of the study . In conclusion , the combination of beclomethasone dipropionate and salmeterol improved pulmonary function and bronchial reactivity earlier than beclomethasone dipropionate alone , while nedocromil sodium improved symptoms but not pulmonary function . Assuming that bronchial reactivity could be an indirect measurement of airway inflammation , overtreatment of asthma in relationship with the classification of asthma severity of the International Guidelines could improve both airway inflammation and the prognosis of airway obstruction .
3208
Intervention_Pharmacological
nedocromil sodium ( NS )
3209
Intervention_Pharmacological
beclomethasone dipropionate ( BDP )
3210
Intervention_Pharmacological
beclomethasone dipropionate
3211
Intervention_Pharmacological
salmeterol
3212
Outcome_Physical
PEF variability
3213
Outcome_Physical
FEV1
3214
Outcome_Physical
bronchial hyperreactivity
3215
Outcome_Physical
FEV1
3216
Outcome_Physical
bronchial reactivity
3217
Outcome_Physical
symptoms
3218
Outcome_Other
and
3219
Outcome_Physical
pulmonary function
3220
Outcome_Physical
pulmonary function
3221
Outcome_Physical
bronchial reactivity
3222
Outcome_Physical
bronchial reactivity
3223
Participant_Condition
subjects with mild-to-moderate asthma .
3224
Participant_Condition
subjects with mild-to-moderate asthma , three groups of 11 patients